We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
There have been very rare reports of posterior reversible encephalopathy syndrome (PRES) and reversible cerebral vasoconstriction syndrome (RCVS) with pseudoephedrine.
Product recall for Hashtag Homes Abeer Reversible Corner Sofa presenting a fire risk.
Relates to Open Reversible Liferafts (ORLs) and UK certification of such liferafts for over capacity as well as the UK servicing exemption.
Assessment of the amount of renewable energy utilised by reversible air-to-air heat pumps in the UK.
A set of key clinical indicators (KCIs) has been developed, for which data were first published in February 2006. The KCI reports are updated annually.
Adopted EU recommendation LSA-014. UK approved recommendation on the use of Marine Evacuation Systems on open reversible liferafts
Special feature article from the March 2018 edition of Energy trends statistical publication.
Advice for medical professionals to follow when assessing drivers with neurological disorders.
Find out about the reverse charge for supplies of services reported within the Construction Industry Scheme (CIS).
A summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices.
The MHRA has reviewed the latest evidence relating to the very rare risk of PRES and RCVS associated with medicines containing pseudoephedrine
Research publications into the cost and performance of technologies which are not currently eligible for the RHI but could be considered for future inclusion.
Increase the frequency of blood pressure monitoring to at least weekly for the first 2 months, and then monitor monthly for the first year and periodically thereafter during treatment, following recent reports of onset of severe hypertension (including rare cases...
Interrupt treatment if posterior reversible encephalopathy syndrome (PRES) is confirmed and resume treatment only once the event is resolved and the benefit of continued treatment outweighs the risk of PRES.
We are providing an update on a retrospective observational study on the risk to children born to men who took valproate in the 3 months before conception and on the need for the re-analysis of the data from this study...
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share your email address with anyone.